The European schizophrenia drug market is estimated to grow modestly, at a CAGR of 1.5%, during the forecast period. The key driving factor of the market in the region is the increasing mental health disorder of the population which is expected to promote the demand for schizophrenia drugs, thereby promoting the growth of the market in the near future. Moreover, in the European region, governments spent an average of $22 per capita on mental health programs and services in 2016. Nearly all the countries in the European region had a stand-alone or integrated mental health policy or plan. The countries had their policy complied fully with international human rights instruments, and a mental health plan or strategy for children and adolescents was available in only 77% of the countries in 2017. Nearly all the countries in Europe have either a stand-alone law or legislation for mental health that was integrated into general health or disability law.

Visit for Global Schizophrenia Drugs Market Report at: https://www.omrglobal.com/industry-reports/schizophrenia-drugs-market

The European schizophrenia drug market is classified on the basis of therapeutic class and treatment. Based on therapeutic class, the market is segmented into second-generation antipsychotics, third-generation antipsychotics, and other therapeutic classes. Among these therapeutic classes, the second-generation antipsychotics are majorly used in therapeutic classes for the treatment of schizophrenia. Based on treatment, the market is bifurcated into oral and injectables. The oral treatment solution dominates the market due to the presence of a large number of drug manufacturing companies in the country.

Geographically, the European schizophrenia drug market is segmented into Germany, the UK, France, Italy, Spain, and the rest of Europe. Germany contributed the major share in the European schizophrenia drug market. The growth is owing to the various healthcare facilities and well-developed healthcare infrastructure. UK and France have a world-class healthcare system providing a stable platform for the growth of the market in the respective countries. Apart from the major European countries, Switzerland, the Netherlands, Denmark, Norway Ireland, Hungary, and Belgium are some other countries of Europe that are providing a significant contribution to the growth of the schizophrenia drugs market.

The companies which are contributing to the growth of the European schizophrenia drugs market include Allergan PLC, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the European schizophrenia drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. European Schizophrenia Drugs Market Research and Analysis by Therapeutic Class
2. European Schizophrenia Drugs Market Research and Analysis by Treatment

The Report Covers

• Comprehensive research methodology of the European schizophrenia drug market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European schizophrenia drug market.
• Insights about market determinants which are stimulating the European schizophrenia drugs market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.